Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients by McEvoy, Ashleigh et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
2018 
Correlation between circulating tumour DNA and metabolic 
tumour burden in metastatic melanoma patients 
Ashleigh McEvoy 
Edith Cowan University, a.mcevoy@ecu.edu.au 
Lydia Warburton 
Zeyad Al-Ogaili 
Leisl Celliers 
Lesley Calapre 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
10.1186/s12885-018-4637-6 
McEvoy, A. C., Warburton, L., Al-Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., ... & Gray, E. S. (2018). Correlation 
between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC cancer, 
18(1), 726. Available here. 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/4527 
Authors 
Ashleigh McEvoy, Lydia Warburton, Zeyad Al-Ogaili, Leisl Celliers, Lesley Calapre, Michelle R. Pereira, 
Muhammad A. Khattak, Tarek M. Meniawy, Michael Millward, Mel R. Ziman Dr, and Elin S. Gray 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/4527 
RESEARCH ARTICLE Open Access
Correlation between circulating tumour
DNA and metabolic tumour burden in
metastatic melanoma patients
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Muhammad A. Khattak1,4,5, Tarek M. Meniawy2,5, Michael Millward2,5, Melanie Ziman1,6 and Elin S. Gray1,7*
Abstract
Background: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for
non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of
metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients’
overall metabolic tumour burden (MTB).
Methods: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and
metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed
tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR).
Results: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA
levels and MTB (p < 0.001). CtDNA was not detectable in patients with an MTB of ≤10, defining this value as the
lower limit of tumour burden that can be detected through ctDNA analysis by ddPCR.
Conclusions: We showed that ctDNA levels measured by ddPCR correlate with MTB in treatment naïve metastatic
melanoma patients and observed a limit in tumour size for which ctDNA cannot be detected in blood.
Nevertheless, our findings support the use of ctDNA as a non-invasive complementary modality to functional
imaging for monitoring tumour burden.
Keywords: Circulating tumour DNA, ctDNA, Metabolic tumour burden, Tumour lesion glycolysis, Melanoma, Droplet
digital PCR
Background
Melanoma is an aggressive form of skin cancer that is
increasing in prevalence worldwide [1]. Metastatic mel-
anoma is a highly aggressive and difficult to treat cancer,
particularly when patients present with advanced-stage
disease that is unresectable [2]. Recent advances in un-
derstanding the molecular mechanisms of melanoma
oncogenesis and immune evasion have resulted in the
introduction of BRAF and immune checkpoint inhibiting
agents. These new treatments have improved the melan-
oma survival [3–6], with the greatest treatment benefit
observed when treatment is initiated at a lower disease
burden [2, 7–9].
In patients with advanced stage melanoma, treatment
decisions are based upon clinical and imaging findings.
In recent years, positron emission tomography with
2-deoxy-2[fluorine-18] fluoro-D-glucose integrated with
computed tomography (FDG PET/CT) has emerged as a
powerful imaging tool for initial staging and evaluating
treatment response in metastatic melanoma [10, 11].
18F–FDG is a radio labelled glucose analogue which re-
flects tumour metabolic activity. Commonly, FDG PET/
CT is used to determine tumour burden as it provides a
high tumour-to-background intensity ratio which facili-
tates computer generated measurements of total body
metabolic tumour volume (MTV) and total lesion
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glycolysis (TLG) from which metabolic tumour burden
(MTB) can be quantitatively calculated [12, 13].
As a blood-based biomarker, circulating tumour DNA
(ctDNA) offers a non-invasive and easily accessible
method of providing a real-time “snap shot” of tumour
burden. The level of ctDNA sensitivity however differs
between tumour types, AJCC stages, mutant forms and
between patients [14]. In AJCC stage IV melanoma pa-
tients, ctDNA has been recognised as a valuable bio-
marker for tumour genetic profiling, monitoring disease
progression, response to therapy and as a predictor of
clinical outcome [15–23]. Whilst, ctDNA has been de-
tected in 73–89% of patients prior to therapy initiation
[15, 16, 19, 24] and the absence of ctDNA in these pa-
tients has been suggested as a prognostic marker for a
better disease outcome [19], the level of overall tumour
burden at which ctDNA can be detected has not yet
been quantified.
Numerous platforms are available for the detection of
ctDNA, however the droplet digital PCR (ddPCR) plat-
form has been shown to be the most sensitive, capable
of detecting mutant DNA (such as BRAF V600E) at
0.001% frequency abundance [25, 26]. The lower limit
in tumour size that shed detectable amounts of ctDNA
into the blood is however unclear, and it may vary be-
tween cancer types. This information is critical for clin-
ical validation of the efficacy ctDNA as a non-invasive
complimentary method to functional imaging for moni-
toring of tumour burden in melanoma patients.
Here we determined the levels of ctDNA measured by
ddPCR targeting tumour specific mutations in a cohort
of 32 treatment naive stage IV melanoma patients. We
evaluated whether the presence of ctDNA was associated
with progression free survival and whether ctDNA levels
correlated with MTB measured by FDG PET/CT.
Methods
Patient and sample collection
We retrospectively selected 32 from a cohort of Ameri-
can Joint Committee on Cancer (AJCC) 7th Edition,
stage IV melanoma patients enrolled in a multi-centre
study from February 2013 to May 2017. Inclusion cri-
teria incorporated patients whose plasma sample was
collected within 8 weeks from an FDG PET/CT scan
and before any systemic therapy (See Additional file 1
for a detailed list of timing from FDG PET/CT scan to
collection of bloods). As part of the patients’ routine
diagnostic work out, BRAF mutation testing were com-
pleted prior to enrolment in the study. Additional muta-
tional profiling for those patients that were considered
BRAF wild-type was conducted on tumour tissue using
Next Generation Sequencing (NGS). Written informed
consent was obtained from all patients under approved
Human Research Ethics Committee protocols from
Edith Cowan University (No. 11543) and Sir Charles
Gardner Hospital (No. 2013–246), Western Australia.
18F-labeled fluorodeoxyglucose positron emission
tomography/computed tomography
FDG PET/CT scans were performed on combined PET/
CT scanners at approved nuclear medicine centres in
Perth, Western Australia. After a minimum fasting
period of 6 h, patients were injected with 5 MBq pr. kg
±10% of 18FDG (minimum 200 MBq and maximum
600 MBq). Positron emission tomography was per-
formed on patients with serum glucose levels below
11 nmol/l at an acquisition time of 3 min per bed pos-
ition. To determine anatomical location and for attenu-
ation correction purposes, a whole-body low-dose
computed tomography scan was performed. Details of
the imaging cameras are outlined (see Additional file 2).
After being used for routine clinical purposes, all images
were reviewed retrospectively and independently by two
experienced nuclear medicine physicians, blinded to the
ctDNA analysis. The MTV is calculated from the max-
imum length of the lesion using CT images obtained
from the FDG PET/CT imaging data and the TLG is cal-
culated as MTV x mean SUV in the volume [12]. Ana-
lysis was conducted on a Siemens Syngo workstation
(Siemens Healthcare GMbH) with each specialist inde-
pendently reporting the global TLG (MTB) and the glo-
bal MTV in cm3, as per Additional file 2. An average of
the two scores provided by the nuclear medicine physi-
cians was used for final analysis.
Plasma sample preparation and DNA extraction
Blood samples were collected from stage IV melanoma
patients, prior to initiation of any systemic therapy, into
EDTA vacutainer tubes and stored at 4 °C. Plasma was
separated within 24 h by centrifugation at 1600 g for
10 min, followed by a second centrifugation at 2000 g
for 10 min, and then stored at -80 °C until extraction.
Cell free DNA (cfDNA) was isolated from between 1 to
5 mL of plasma using the QIAamp Circulating Nucleic
Acid Kit (Qiagen) as per the manufacturer’s instructions
and eluted in 40 μl AVE buffer (Qiagen) and stored at
-80 °C until ctDNA quantification.
CtDNA quantification
CtDNA was quantified by ddPCR as previously described
[16, 27]. Briefly, a PCR mixture containing 1 x ddPCR
supermix, primer/probe sets for BRAF [see Add-
itional file 2] (custom synthesized by Life Technologies),
NRAS (Bio-Rad) or KIT (Bio-Rad) and 5 or 8 uL cfDNA
were emulsified with droplet generation using the Auto-
matic Droplet Generator (AutoDG, Bio-Rad). Amplifica-
tions were performed using cycling conditions previously
described [16]. Droplets were analysed through a QX200
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droplet reader (Bio-Rad) and data was analysed using
QuantaSoft analysis software (Bio-Rad). To ensure the ac-
curacy of results, each sample was tested minimally in du-
plicate. For quantification, a minimum of 10,000
acceptable droplets per 20 uL reaction was required.
Statistical analysis
Association between patient characteristics and ctDNA
positivity or negativity was calculated by Fisher’s exact
tests or unpaired T-test where appropriate. To assess the
inter-observer agreement, Pearson’s correlation analysis
was performed and an evaluation of bias and precision
was performed using Bland Altman analysis [28]. The
correlation between MTV and MTB and the number of
mutated copies of ctDNA was evaluated using Pearson’s
correlation after log-transformation of both variables.
Progression free survival (PFS) was calculated as the
time from the date of initiating therapy to the date of
first reported progressive disease (PD) or censored with
stable disease at the most recent visit. Median PFS was
calculated using the Kaplan-Meier method and com-
pared using the log-rank test. Cox proportional hazards
regression analyses were performed to examine associ-
ation of ctDNA, and other variables with PFS. Multivari-
ate Cox regression models were evaluated using a
stepwise approach with bidirectional elimination to de-
termine the best fit model. Confidence intervals were set
at 0.05 and significance levels are reported as P < 0.05.
Statistical analyses were performed using Statistical
Package for Social Sciences for Window version 22
(SPSS, Chicago, IL) and plotted using GraphPad Prism
version 5.
Results
Cohort
A total of 32 patients with stage IV metastatic cutane-
ous melanoma were included in the study. Patient char-
acteristics are shown in Table 1. The median time
between blood collection and PET/CT was 1.9 weeks
(range: 0.1–8 weeks, see Additional file 1). Patients
were treated with targeted therapy and/or immunother-
apy (see Additional file 1). After a median follow-up of
64.4 weeks (95% CI: 46.2–82.6 weeks), 11 patients pro-
gressed whereas a large proportion retained control of
the disease.
Evaluation of plasma ctDNA
Of the 32 tumour samples analysed, at least one mutation
was known to be present with 94% of the samples har-
bouring a mutation in BRAF V600. Other mutations de-
tected in ctDNA included KIT L576P (patient 28) and
NRAS Q61L (patient 32) (Fig. 1). CtDNA was detected in
23 patients with a median concentration of 38 copies/mL
of plasma (range: 1.6–52,440 copies/mL). The remaining 9
patients had no detectable ctDNA. A comparison of pa-
tient characteristics was conducted between the ctDNA
positive and ctDNA negative patients (Table 2). Significant
differences were evident in sex (p = 0.05), with a higher
proportion of males having detectable ctDNA than fe-
males, and M stage (p = 0.03), with M1c (patients with vis-
ceral metastases) more likely to have detectable ctDNA
than M1a and M1b. When evaluating for PFS, patients
with detectable ctDNA had a significantly shorter median
PFS (39.14 weeks) than patients with undetectable ctDNA
(102.29 weeks, P = 0.002; Fig. 2).
Inter-observer analysis of MTV and MTB
MTV and MTB were assessable in all patients from PET/
CT scans. A good correlation (R2 =. 0.978 and 0.998 re-
spectively) was observed between the two independent
scores (see Additional file 3), with Bland-Altman plots
showing a good agreement between the two specialists,
with all but one observation falling within 95% CI.
Correlation between ctDNA copies / mL and MTV/MTB
A significant correlation (R2 = 0.7054, P < 0.0001)
(Fig. 3a) was found between the copies of ctDNA per
mL of plasma and the global TLG or MTB. Similarly, a
weaker but none the less significant correlation was ob-
served (R2 = 0.6949, P < 0.0001) (Fig. 3b) between the
copies of ctDNA per mL of plasma and the MTV.
CtDNA was undetectable in all patients with an MTB
value of ≤10, which suggests that this is the lower limit
Table 1 Patient characteristics
Total
(n = 32)
Gender
Male 62.5 (20)
Female 37.5 (12)
Age
Median years (range) 57 (25–83)
Stage
M1a 12.5 (4)
M1b 6.3 (2)
M1c 81.3 (26)
Performance status, ECOG
0 65.6 (21)
1- 2 34.4 (11)
LDH
Not elevated 34.4 (11)
Elevated 21.9 (7)
Not available 43.8 (14)
Abbreviation: ECOG Eastern Cooperative Oncology Group, LDH Lactate
dehydrogenase. * Significant difference p < 0.05
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of disease burden at which ctDNA can be detected.
CtDNA was also undetectable in three cases with MTB >
10, namely patients 10, 29 and 31 (Fig. 1). CfDNA was
isolated from 1 mL of plasma for patients 29 and 31 and
patient 10 had a cerebellar lesion only brain metasta-
sis which may reduce our capacity to detect ctDNA
in these cases.
Multivariate cox regression analyses of PFS
Finally, in a univariate Cox regression analysis, detect-
able ctDNA, high MTB and M1c disease were found to
be significantly associated with decreased PFS (Table 3).
A multivariate Cox regression analysis revealed that
these three variables do not independently predict PFS.
Using a stepwise approach with bidirectional elimination
to determine the best fit model, we found that ctDNA
explains most of the differences in PFS with an adjusted
HR = 7.658 (CI 95% 1.762–33.283) (Table 3) after con-
trolling for sex, age and ECOG status.
Discussion
Here we demonstrated a significant correlation between
the ctDNA levels in plasma and MTB measured by
PET/CT in metastatic melanoma patients. Moreover, we
observed a threshold for detecting ctDNA at an MTB
score of ≤10. Finally, we confirm previous reports show-
ing that undetectable ctDNA is associated with longer
PFS.
With regards to patients with undetectable ctDNA,
several cases are worth highlighting. In our study, one
case (patient 4) with subcutaneous metastases only and
noted to have low disease burden, was found negative
for plasma ctDNA. Previously, subcutaneous metastases
have been shown to be associated with low levels of
ctDNA, despite extensive disease [22]. Patients 16, 31
and 32 had nodal metastases only and ctDNA was not
detectable. Whilst Wong et al. [22] have shown that pa-
tients with nodal involvement often display high levels
of ctDNA, we did not confirm this finding. It is worth
noting that no other patients in our cohort had nodal
Fig. 1 Overview of disease burden and ctDNA for 32 patients with melanoma. Patients are ordered according to metabolic tumour burden
(MTB). Other indications of tumour burden such as metabolic tumour volume (MTV) and site of metastasis are compared with circulating tumour
DNA (ctDNA, copies/mL of plasma) levels and site of metastasis. CtDNA was measured by droplet digital PCR targeting the mutations indicated.
*denotes cases for which cfDNA was extracted from 1 mL of plasma. †denotes KIT L576P, ‡denotes NRAS Q61L
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disease alone, thus extrapolation of our results suggest-
ing that ctDNA is undetectable in node only disease
should be considered with caution. Moreover, this may
be confounded by the fact that in two cases (patients 16
and 32) the MTB was below our threshold of 10. The
third patient (patient 31) had an MTB of 33.49 but the
lack of ctDNA could be attributed to the fact that
cfDNA was extracted from only 1 ml of plasma.
Undetectable ctDNA in patients 9, 10 and 30 may be
explained by the sites of their metastatic disease, nodal
and brain (patient 9) and brain only (patient 10 and 30).
Previously, low or undetectable ctDNA levels have been
observed in patients with brain metastases [22, 29, 30].
One significant outlier is patient 29, where despite
having bone metastases and a significant MTB, we were
unable to detect ctDNA. Bone metastases have previ-
ously been associated with high levels of ctDNA [22]. In
this case, cfDNA was also extracted from only 1 mL of
plasma which is likely to have a significant impact on
detection levels of ctDNA [31].
Remarkably patient 28 (with nodal and liver metasta-
ses) had undetectable ctDNA however, MTB was ≤10.
No obvious limitations were evident in this case, particu-
larly with regards to the volume of plasma collected.
Thus, we are confident that with our current assay sensi-
tivities, we are not able to detect ctDNA in patients with
a MTB value of ≤10, regardless of disease site or muta-
tion. Nevertheless, this observation needs to be corrobo-
rated in larger studies, taking in consideration diverse
mutated genes and the site of metastases.
To our knowledge, this is the first study in melanoma
that has directly compared the level of ctDNA with the
exact MTB calculated from the sum of TLG for all eva-
luable lesions. Recently, Wong et al. [22] showed that
ctDNA levels correlate with qualitative analysis of whole
body MTV in metastatic melanoma patients. Similar to
our findings, a strong correlation was observed between
ctDNA levels and MTV (r = 0.61; P < 0.001). Whilst it is
difficult to make a direct comparison between this study
and our own due to the different methodologies
employed to detect ctDNA (digital PCR and targeted se-
quencing) and different reporting mechanisms of MTV
(Wong reported results in mL, whilst we reported re-
sults in cm3), it is interesting to note there is a remark-
able difference in the median levels of plasma ctDNA
reported by both studies. Wong et al. reported a median
Table 2 Comparisons of clinical characteristics between
patients with and without ctDNA present (N = 32)
ctDNA+ ctDNA- P
value(n = 23) (n = 9)
Gender
Male 85.0 (17) 15.0 (3)* 0.05*
Female 50.0 (6) 50.0 (6)
Age
Median years (range) 58 (25–78) 62 (34–83) 0.24
Stage
M1a or b 16.7 (1) 83.3 (5) 0.03*
M1c 84.6 (22) 15.4 (4)
Performance status, ECOG
0 69.6 (16) 30.4 (5) 0.68
> 0.99 63.6 (7) 36.4 (4)
LDH
Not elevated 63.6 (7) 36.4 (4) 0.60
Elevated 85.7 (6) 14.3 (1)
Not available 71.4 (10) 28.6 (4)
Abbreviation: ECOG Eastern Cooperative Oncology Group, LDH Lactate
dehydrogenase. *Significant difference p < 0.05
Fig. 2 Kaplan-Meier curve for progression free survival (PFS) according to the presence of circulating tumour DNA (ctDNA) in plasma. In patients
with detectable ctDNA, a median PFS of 33.29 weeks was observed
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ctDNA concentration of 1112 copies/mL of plasma (range
63–97,000) which is considerably higher than the copies/
mL of plasma that we reported, indicating an enrichment
of patients with lower disease burden in our study. Finally,
our measurements incorporated PET parameter TLG to
define all measureable lesions combined with the meta-
bolic activity of each tumour, thus measuring both tumour
volume and aggressiveness. This approach provides a
comprehensive score of not only of tumour burden but
also of tumour activity and therefore, an overall perspec-
tive of the disease status of patient.
In line with our study, the presence of ctDNA has
been directly correlated with patient survival and MTB
in advanced stage non-small cell lung cancer (NSCLC)
[12]. This study assessed allele frequency measured by
NGS in 24 NSCLC patients and MTB (calculated from
the sum of TLG for all evaluable lesions) and found a
significant correlation (P = 0.001). The authors also re-
ported a significantly shorter median overall survival
(OS) in patients with detectable ctDNA compared to
those with no detectable ctDNA. In our study, we have
specifically chosen not to assess OS as this endpoint in-
cludes death from any cause, and thus is influenced by
co-morbidities and access to systemic therapies over dif-
ferent periods of time. For this reason, our analysis fo-
cused on PFS, which was significantly shortened in
patients with detectable ctDNA. Finally, multivariate
Cox regression analyses demonstrated that ctDNA is not
an independent variable but rather a reflection of other
disease burden measurements such as MTB and disease
stage.
There are a number of noteworthy limitations to our
study, largely associated with its retrospective nature.
Firstly, the timing of blood collections in accordance with
PET/CT imaging was varied. In the Winther-Larsen and
colleagues study [12], blood samples were collected at the
time of inclusion into the study, and PET/CT imaging.
This resulted in a median interval of 2 days between im-
aging and blood draw, which is considerably shorter than
our median of 1.9 weeks. However, for both studies the
timing between blood collection and imaging may be an
important factor to consider. Given that ctDNA has a
half-life of less than 2 h and have been shown to increase
as new lesions become apparent [32], ideally blood draw
should be conducted immediately after imaging to ensure
that ctDNA detected is a true reflection of lesions identi-
fied in the image. Importantly, in all our cases, plasma was
collected after imaging and prior to treatment. Secondly,
PET/CT imaging was conducted at different institutions,
which may have resulted in inter-institutional differences
in quality control and scanning [33]; the use of multiple
scanner models has been associated with variability in the
a b
Fig. 3 Correlation between circulating tumour DNA (ctDNA) levels and disease burden. Correlation between ctDNA levels in copies/mL of plasma
and MTB (a) or MTV (b) assessed by FDG-PET imaging. Analysis was performed by using Spearman rank correlation
Table 3 Factors associated with PFS
Factor Variable Univariate analysis Multivariate analysis
p-value HR CI (95%) p-value HR CI (95%)
ctDNA positive/negative 0.009* 6.973 1.612–30.165 0.007* 7.658 1.762–33.283
Age Continuous 0.619 0.992 0.961–1.024 0.558 0.988 0.949–1.029
Sex Male vs. Female 0.419 0.834 0.537–1.295 0.548 1.184 0.682–2.058
ECOG 0–2 0.747 1.127 0.544–2.337 0.526 1.284 0.593–2.781
MTB$ > 34 vs. ≤34 0.018* 5.845 1.356–25.206
Stage M1a,b vs. M1c 0.035* 1.454 0.218–0.945
Abbreviations: ctDNA circulating tumour DNA, ECOG Eastern Cooperative Oncology Group, MTB Metabolic Tumour Burden, HR hazard ratio, CI confidence interval.
*Statistically significant. $Dichotomised at First Interquartile
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standard uptake of FDG readings [34]. We did not how-
ever observe any substantial deviation in the correlation
between ctDNA and MTB due to scanner models (see
Additional file 4). Finally, we acknowledge that this cohort
is heavily biased for BRAF V600 mutated cases, and future
studies should address this across multiple mutations.
Conclusions
In conclusion, the significant correlation of ctDNA with
MTB in treatment naïve metastatic melanoma patients
in this study suggests that quantification of ctDNA be-
tween scans may provide a minimally invasive option
with which to detect changes in disease burden in mel-
anoma. We observed a limit in tumour size for which
ctDNA can be detected in blood, suggesting that detec-
tion of ctDNA in patients with low disease burden ne-
cessitates further improvements in the technology to
increase sensitivity.
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